R
Robert S. Smith
Researcher at Cornell University
Publications - 78
Citations - 5899
Robert S. Smith is an academic researcher from Cornell University. The author has contributed to research in topics: Wage & Public sector. The author has an hindex of 30, co-authored 75 publications receiving 5779 citations. Previous affiliations of Robert S. Smith include University of Connecticut.
Papers
More filters
ReportDOI
Comparable Worth in the Public Sector
TL;DR: In this article, the authors discuss the case for and against comparable worth from the perspective of analystical economists and present estimates of systems of demand curves for state and local government employees.
Journal ArticleDOI
Comparable-Worth Wage Adjustments and Female Employment in the State and Local Sector
TL;DR: In this paper, the authors simulated the likely effects of a comparable-worth wage adjustment policy in the state and local sector on female employment in the sector using data from the 1980 Census of Population.
Journal ArticleDOI
Biodiversity patterns of nutrient-rich fish ponds and implications for conservation
Alexander Wezel,Beat Oertli,Véronique Rosset,Florent Arthaud,Benjamin LeRoy,Robert S. Smith,Sandrine Angélibert,Gudrun Bornette,Dominique Vallod,Joël Robin +9 more
TL;DR: Investigation of 84 fish ponds in the Dombes region, France with five taxonomic groups found that nutrient-rich water bodies can collectively host high species richness at the regional scale, and that the conservation of biodiversity of fish ponds must be established at a regional scale.
Posted Content
Pension Funding in the Public Sector
TL;DR: In this paper, the determinants of pension funding in the public sector were explored and several hypotheses about public employer pension funding practices, using a new data set describing financial and other characteristics of state, local, and teacher plans.
Journal ArticleDOI
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors
Maja J.A. de Jonge,Cornelis J. A. Punt,Alex Sparreboom,Andre S. T. Planting,Marlies E. W. J. Peters,Jacqueline van de Schraaf,Ann L. Jackman,Robert S. Smith,Pieter H.M. De Mulder,Jaap Verweij +9 more
TL;DR: DLTs in this phase I study of oral ZD9331 were myelosuppression and skin toxicity and the recommended dose for phase II studies of oral D9331 is 20 mg od for 5 consecutive days, every 3 weeks.